Browse by category

Results from Syntis Bio’s 28-day multiple ascending dose (MAD) portion of its Phase 1/1b SYNTIETY-1 clinical trial, evaluating SYNT-101 as a potential treatment of obesity, revealed that SYNT-101 was well tolerated at all dose levels in the MAD cohorts (n=23), with no discontinuations and no dose reductions in any of the cohorts. SYNT-101 is being developed as a once-daily pill for the treatment of obesity. SYNT-101 works by transiently blocking nutrient absorption in the pro